Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Recent Advances in Optically Controlled PROTAC
View through CrossRef
Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells. To address this issue, researchers are modifying PROTACs using various approaches to enhance their target specificity. This review highlights innovative optically controlled PROTACs as anti-cancer therapies currently used in clinical practice and explores the challenges associated with their efficacy and safety. The development of optically controlled PROTACs holds the potential to significantly expand the clinical applicability of PROTAC-based technology within the realm of drug discovery.
Title: Recent Advances in Optically Controlled PROTAC
Description:
Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells.
However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells.
To address this issue, researchers are modifying PROTACs using various approaches to enhance their target specificity.
This review highlights innovative optically controlled PROTACs as anti-cancer therapies currently used in clinical practice and explores the challenges associated with their efficacy and safety.
The development of optically controlled PROTACs holds the potential to significantly expand the clinical applicability of PROTAC-based technology within the realm of drug discovery.
Related Results
Interpretable PROTAC degradation prediction with structure-informed deep ternary attention framework
Interpretable PROTAC degradation prediction with structure-informed deep ternary attention framework
Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional ligands that form ternary complexes with Protein Of Interests (POIs) and E3 ligases, exploiting the ubiquitin-protea...
Abstract 1685: Overcoming acquired resistance to PROTAC degraders
Abstract 1685: Overcoming acquired resistance to PROTAC degraders
Abstract
Background: Proteolysis-targeting chimera (PROTAC) technology has been widely investigated for cancer treatment and there have been several PROTAC degrader-...
LM-PROTAC: a language model-driven PROTAC generation pipeline with dual constraints of structure and property
LM-PROTAC: a language model-driven PROTAC generation pipeline with dual constraints of structure and property
Abstract
The imperfect modeling of ternary complexes has limited the application of computer-aided drug discovery tools in PROTAC research and development. In this study, a...
Benchmarking of PROTAC docking and virtual screening tools
Benchmarking of PROTAC docking and virtual screening tools
AbstractProteolysis targeting chimeras (PROTACs) are bifunctional compounds that recruit an E3 ligase to a target protein to induce ubiquitination and degradation of the target and...
Nanocarrier-Mediated PROTAC Delivery for Targeted Oncogenic Protein Degradation in Triple-Negative Breast Cancer
Nanocarrier-Mediated PROTAC Delivery for Targeted Oncogenic Protein Degradation in Triple-Negative Breast Cancer
anocarriers have shown great potential in the targeted degradation of oncogenic proteins in triple-negative breast cancer (TNBC), offering a promising approach in cancer treatment....
PROTAC GMP Services v1
PROTAC GMP Services v1
BOC Sciences’ GMP production sites were designed in strict accordance to US-FDA guidelines for GMP Manufacturing. It has passed US-FDA inspections. We provide standard QC tests bef...
PROTAC GMP Services v1
PROTAC GMP Services v1
BOC Sciences’ GMP production sites were designed in strict accordance to US-FDA guidelines for GMP Manufacturing. It has passed US-FDA inspections. We provide standard QC tests bef...
Abstract 1654: Discovery of the first-in-class DOT1L PROTAC degrader
Abstract 1654: Discovery of the first-in-class DOT1L PROTAC degrader
The histone methyltransferase, DOT1L is often dysregulated in MLL-rearranged (MLL-r) leukemia, which leads to hyperactivation of MLL target genes and poor prognosis. This dysregula...